[Taenkang: The first subject has been enrolled in the phase IIb clinical trial of CKBA cream, an innovative drug for rosacea indications of its holding subsidiary] On September 7, Tynekang (301263.SZ) announced that the first subject was enrolled in the phase IIb clinical trial of CKBA cream, a Class 1 innovative drug for the treatment of rosacea, organized by Jiangsu Bochuangyuan Biomedical Technology Co., Ltd., the company’s holding subsidiary. This drug is the world's first innovative small molecule targeting the fatty acid metabolism pathway of T cells and has global independent intellectual property rights from China, the United States, the European Union and Japan. As of now, no Class 1 innovative drugs for the treatment of rosacea have been approved for marketing in China.